Pfizer to Invest $120 Million in COVID-19 Oral Treatment Production

Published on: 

Pfizer will invest $120 million to produce COVID-19 oral treatment in the US.

Pfizer announced on June 6, 2022 that it will invest $120 million in its Kalamazoo, MI facility to support the production of its COVID-19 oral treatment, PAXLOVID. The investment is predicted to create more than 250 additional high-skilled jobs at the company’s Kalamazoo site.

The investment is a step towards the company’s goal to further strengthen its commitment to US manufacturing, increasing its capability to produce and supply treatments and medicines for patients in the United States and around the world. Pfizer has shipped 12 million courses of PAXLOVID across 37 countries, including 5 million courses shipped to the US, and has manufactured almost 17 million treatment courses total, to date.

“Pfizer Global Supply has made the impossible possible, making billions of vaccine doses and now millions of treatment courses to help battle the deadly COVID-19 pandemic,” said Albert Bourla, chairman and CEO of Pfizer, in a press release. “By increasing production at our Michigan facility, we are both helping patients around the world and expanding important manufacturing innovation to the US. This investment builds upon our $5 billion of investments across our manufacturing and distribution portfolio since 2017 to support the ongoing growth of US manufacturing leadership.”


“Pfizer’s Kalamazoo facility has been at the forefront of pharmaceutical manufacturing for more than 135 years through the legacy company Upjohn,” added Mike McDermott, chief global supply officer of Pfizer, in the release. “The Kalamazoo facility uses some of our most innovative manufacturing technology and has been essential in Pfizer’s fight against COVID-19, producing nearly one billion doses of COVID-19 vaccine at the site to date. Through this expansion, we will continue to invest in the next generation of manufacturing and supply chain resilience.”

Source: Pfizer